1,603 results on '"Ljungman, Per"'
Search Results
152. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
153. Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation
154. Consensus Definitions of BK Polyomavirus Nephropathy in Renal Transplant Recipients for Clinical Trials
155. Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study
156. Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients – Study of infectious diseases working party of EBMT
157. Randomized Study of Early versus Late Immunization with Pneumococcal Conjugate Vaccine after Allogeneic Stem Cell Transplantation
158. Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study
159. Viral Infections in Immunocompromised Patients
160. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial
161. Corrigendum: Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
162. Infectious complications and vaccines
163. The EHA Research Roadmap: Infections in Hematology
164. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
165. Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT
166. Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia
167. CD38 Down-Regulation on Ex Vivo Activated and Expanded NK Cells for Cell Therapy Persists after Infusion
168. N-Acetylcysteine Amide Alleviates Cyclophosphamide-Induced Endothelial Damage
169. COVID-19 in Children Following Hematopoietic Cell Transplantation: A Multinational Study of the European Bone Marrow Transplantation Society (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH)
170. Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
171. One step at a time
172. Appearance of IgG to SARS-CoV-2 in saliva effectively indicates seroconversion in mRNA vaccinated immunocompromised individuals
173. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes
174. The challenge of antibiotic resistance in haematology patients
175. Management of post-transplant lymphoproliferative disorders
176. Quality of the hematopoietic stem cell graft affects the clinical outcome of allogeneic stem cell transplantation
177. NK cells expressing inhibitory KIR for non–self-ligands remain tolerant in HLA-matched sibling stem cell transplantation
178. Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions
179. Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
180. β-Herpesvirus Challenges in the Transplant Recipient
181. Epidemiology and outcomes of patients with invasive mould infections: a retrospective observational study from a single centre (2005–2009)
182. How we treat cytomegalovirus in hematopoietic cell transplant recipients
183. Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies
184. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
185. Molecular monitoring of viral infections after hematopoietic stem cell transplantation
186. Long-term follow-up of bone density, general and reproductive health in female survivors after treatment for haematological malignancies
187. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation
188. Anti‐infective prophylaxis, immunization and prevention of late infectious complications
189. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis
190. A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol
191. Vaccination against tick-borne encephalitis (TBE) after autologous and allogeneic stem cell transplantation
192. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
193. Factors associated with poor general health after stem-cell transplantation
194. Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults
195. Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III
196. Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
197. List of Contributors
198. Vaccination of immunocompromised hosts
199. Risk assessment in haematopoietic stem cell transplantation: Viral status
200. Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.